1.53 CALGB 50303, REMoDL-B, & REMS, Orphan Drug Act, and Role of the FDA with Dr. Ameet Sarpatwari - podcast episode cover

1.53 CALGB 50303, REMoDL-B, & REMS, Orphan Drug Act, and Role of the FDA with Dr. Ameet Sarpatwari

Apr 11, 20191 hr 46 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

We begin this episode with a discussion of two recent clinical trials in lymphoma: CALGB 50303 and REMoDL-B, respectively published in the Journal of Clinical Oncology and The Lancet Oncology. We include a primer on the history of lymphoma and the development of R-CHOP. We follow that with an in-depth interview with Dr. Ameet Sarpatwari of the Harvard Medical School on Risk Evaluation and Mitigation Strategies (REMS), the Orphan Drug Act, and, broadly, the purpose of the US FDA. CALGB 50303: doi.org/10.1200/JCO.18.01994 REMoDL-B: doi.org/10.1016/S1470-2045(18)30935-5 Dr. Sarpatwari's online course: https://www.edx.org/course/the-fda-and-prescription-drugs-current-controversies-in-context Back us on Patreon! www.patreon.com/plenarysession
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast
1.53 CALGB 50303, REMoDL-B, & REMS, Orphan Drug Act, and Role of the FDA with Dr. Ameet Sarpatwari | Plenary Session - inactive due to federal service podcast - Listen or read transcript on Metacast